Paris, France — 6 January 2023 at 05:00 pm CET —Lysogene (FR0013233475 – LYS), a…
Paris, France — 14 December 2022 at 08:00 am CET — Lysogene (FR0013233475 – LYS),…
Paris, France — 6 December 2022 — Lysogene (FR0013233475 – LYS), a phase 3 gene…
Completion of treatment and 6 months follow-up for the last patient enrolled in Stage 1…
In the cohort of patients enrolled before the age of 30 months, a statistically significant…
Live webcast to be hosted on Wednesday, November 23, 2022 at 1:30 pm CET Paris,…
Cash and cash equivalents of €6.1 million[1] as of 30 September 2022 Paris, France —…
Full data analysis of AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in MPS…
Paris, France —16 September 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS), a…
Cash and cash equivalents of €7.7 million[1] as of 30 June 2022 Paris, France —…
- 1
- 2